Alectinib, a central nervous system (CNS) penetrant, was recognized through the ALEX [4] and J-ALEX trials [5] to be better suited for the treatment of ALK-positive NSCLC due to its propensity for CNS metastases. The gene discussed is ALK; the disease is non-small cell lung carcinoma.